Skip to main content
Clinical Trials/IRCT20181015041353N1
IRCT20181015041353N1
Recruiting
Phase 3

Study of the effectiveness of Tiotropium bromide in patients with severe asthma

Zahedan University of Medical Sciences0 sites60 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Zahedan University of Medical Sciences
Enrollment
60
Status
Recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Zahedan University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Patients with severe asthma who have been treated with routine anti\-asthma drugs
  • Being under treatment with routine anti\-asthma drugs
  • Labeled as grade 4 or 5 of asthma
  • Age of 18 years and more

Exclusion Criteria

  • lactation (Breastfeeding)
  • Using hormonal contraceptives drugs
  • High pregnancy probability
  • Chronic obstructive pulmonary disease (COPD)
  • Having other pulmonary diseases
  • Infection of the respiratory system
  • Audio cord performance dysfunction
  • smokers with more than 10 pack per year
  • History of taking muscarinic anticholinergic drugs
  • History of taking other anticholinergic drugs

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Evaluation of therapeutic effect of Tiotropium Bromide in early stages of chronic obstructive pulmonary disease in patients of subspecialty clinics of Isfahan university of medical science in 2018 - 201
IRCT20190524043684N1Esfahan University of Medical Sciences92
Completed
Not Applicable
Efficacy of Tiotropium bromide (Spiriva 2.5 microgram Respimat 60 puffs) for chronic asthmatic cough refractory to intensive therapiesasthma
JPRN-UMIN000021064agoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology58
Active, not recruiting
Not Applicable
Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation-TIBROMUC- - TIBROMUCAnticholinergic bronchodilators, such as ipratropium bromide, may be used in combination with beta adrenergic agonists as SAlbutamol to produce bronchodilation in excess of that achieved by either agent alone.Therefore we will treat both study arms with salbutamol. One group A will receive tiotropium bromide with salbutamol, while the other group B will receive salbutamol.MedDRA version: 8.1Level: LLTClassification code 10010952Term: COPD
EUCTR2006-005819-10-DEPhilipps-University Marburg
Completed
Phase 4
Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During ExerciseCOPD
NCT00412204McMaster University20
Completed
Not Applicable
Efficacy of Tiotropium Bromide Hydrate on human bronchial mucocillially movement using bronchoscopic specimeRespiratory disease requiring bronchoscopy
JPRN-UMIN000011351Respiratory medicine and oncology Gifu Municipal Hospital50